PHC Launches LiCellMo TM Live Cell Metabolic Analyzer for Real-Time Visualization of Cellular Metabolism in Cell and Gene Therapies
PHC Corporation Biomedical Division (headquarters: Chiyoda-ku, Tokyo, President: Nobuaki Nakamura; hereafter Biomedical Division) announced today the commercial launch of LiCellMo, a live cell metabolic analyzer that allows researchers to visualize metabolic(*1) changes in cell cultures, providing a more complete picture of cell activity for research uses in cell and gene therapies (CGT). LiCellMo uses PHC’s proprietary high-precision In-Line monitoring technology(*2), which enables continuous measurement of cellular metabolites in culture medium without needing to interrupt the experiment for sampling. LiCellMo will be launched in Japan in September, followed by a launch in other select geographies in October.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903521355/en/
Left: Controller (MLC-AC0-P*) / Right: Detector (MLC-AD240A-P*) / Bottom: Sensor module (MLC-AS240A-PW) (Graphic: Business Wire)
As CGT gains recognition as a promising treatment approach for previously hard-to-treat diseases, research and development of CGT products such as CAR-T therapy(*3) for cancer treatment are progressing rapidly. Tracking cellular metabolism—the series of reactions that provide the energy required to sustain life—is a key component of process development for CGT products, as well as stem cell research(*4) including iPS cells and cancer immunology research. For the production of high-quality CGT products, it is essential to accurately assess cell growth and differentiation and create an optimal cell culture environment. The need for precise analysis of metabolic changes is especially important to support processes such as the transition from 2D cell culture techniques (*5) to more complex 3D cell culture methods, including organoids (*6).
Conventional methods for evaluating cell metabolism require researchers to take periodic samples of the culture medium, which makes it difficult to monitor changes in cell conditions over time, as the measurements are typically discrete data points. Repeated sampling also carries the risk of contamination. Reproducibility issues can also occur in culture manipulation, as the standards for assessing cell states depend on the skill and experience of the researcher. Consequently, researchers need a method to continuously monitor the state of cells based on objective and quantitative assessment indicators without the need for repeated medium sampling.
The new LiCellMo live cell metabolic analyzer overcomes these challenges encountered during research and contributes to the accelerated practical application of new treatment modalities. LiCellMo provides continuously measured data on key cellular metabolic pathways, giving researchers a precise picture of previously unobservable changes in the state of cells over time. By providing continuous and accurate metabolic data, LiCellMo will allow researchers to make more informed decisions. This will help contribute to novel research findings and important advances in therapies. In addition, the LiCellMo can be easily installed in a laboratory’s existing CO2 incubator with no changes to the usual culture environment, and the sensor module will be the only PHC’s proprietary consumable required for use. As a result, it offers researchers a flexible solution to challenges faced in conventional cell culture methods.
Product benefits |
|
LiCellMo has been used globally in beta-testing at a number of research institutes and pharmaceutical companies since 2023. One beta tester was Masaki Kimura, a Research Associate in the laboratory led by Takanori Takebe, Associate Professor, University of Cincinnati Department of Pediatrics, Director of Commercial Innovation at the Center for Stem Cell and Organoid Medicine (CuSTOM), an expert in the production of liver organoids from induced pluripotent stem cells (iPSCs) in the Division of Gastroenterology, Hepatology and Nutrition at Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA. Kimura said, “The challenge of the conventional metabolic measurements of cell cultures is that the differences with each time point are so large that it’s difficult to detect the dynamic changes in the metabolism.” Using LiCellMo allowed his team to collect far more detailed information from the liver organoids they had created than was previously possible.
Chikara Takauo, Director of PHC Corporation and Head of Biomedical Division, said, “I am very pleased to see the launch of LiCellMo. The In-Line monitoring technology featured in this live cell metabolic analyzer is newly developed proprietary technology building on the core technology of blood glucose sensor, the main product developed by IVD. This demonstrates the synergy between the Biomedical Division and the IVD Division. We believe that it will give researchers the opportunity to gain unprecedented new knowledge on cell metabolism in the fields of cancer immunology and stem cell research, and in the manufacture process for new treatments in those fields. With the launch of LiCellMo, we aim to contribute to the evolution of modalities by accelerating the creation of innovative solutions for QCD (quality, cost, and delivery) challenges in the CGT product manufacturing process, moving towards the early spread of CGT.”
Notes
(*1) A series of biochemical reactions within cultured cells that produce the energy required for cellular functions and survival.
(*2) A technology that enables continuous measurement of cellular metabolites in culture medium without the need for sampling, achieved by maintaining constant immersion in the medium.
(*3) A treatment for refractory cancers that are difficult to completely destroy through the body’s natural immune response alone. This treatment involves the collection of the patient’s T cells, genetically modifying them to produce a specialized protein called a chimeric antigen receptor (CAR), and then reintroducing these CAR-T cells into the patient.
(*4) Research focused on cells with the ability to divide and produce identical cells, as well as differentiate into other cell types.
(*5) Methods for culturing cells on a flat surface, where cells adhere to the bottom of a plastic vessel, such as a culture dish or flask.
(*6) Methods for culturing cells on 3D structures, where cells grow on a 3D substrate that mimics natural tissue environments.
About the Biomedical Division of PHC Corporation
Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO:6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its laboratory and equipment and services including CO2 incubators and ultra-low temperature freezers.
www.phchd.com/global/phc
About PHC Holdings Corporation
PHC Holdings Corporation (TOKYO:6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Wemex Corporation, and Mediford Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. The consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries and regions. PHC Group is a collective term referring to PHC Holdings Corporation and its subsidiaries.
www.phchd.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903521355/en/
Contacts
Contact for product and service:
Masayo Okada
Marketing Department, Biomedical Division
PHC Corporation
Email: masayo.okada@phchd.com
Contact for IR and media:
Hiroko Arai
Investor Relations & Corporate Communications Department
PHC Holdings Corporation
Tel: +81-3-6778-5311
Email: phc-pr@gg.phchd.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge ® (omidubicel-onlv)11.3.2025 13:00:00 EET | Press release
Ayrmid Pharma Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics and RoslinCT, a world leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced their intent to enter into a strategic partnership for the production of Omisirge, a commercial product for the treatment of hematologic malignancies commercialized in the US by Gamida Cell Inc, a subsidiary of Ayrmid Pharma Ltd. It is the intent of the two companies to enter into an agreement whereby RoslinCT will perform technology transfer and commercial manufacture of Gamida Cell’s Omisirge. The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA approved and launched in 2023. It is the intent of the two companies that the technology transfer and commercial manufacturing will take place in RoslinCT's state-of-the-art, purpose-built cell therapy CGMP manufacturing facility in Hopkinton, MA. “As part of our globa
Kinaxis to Unveil the Next Phase of AI Innovation at Kinexions 202511.3.2025 13:00:00 EET | Press release
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is set to unveil new artificial intelligence capabilities in its Maestro™ platform at Kinexions North America 2025, the company’s global innovation conference. These AI capabilities are designed to accelerate the value that AI can create in supply chains, helping companies navigate an increasingly volatile global trade environment - whether they are just beginning their AI journey or already leveraging advanced automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311610609/en/ The company will introduce AI agents that users can interact with to monitor, predict, and take action in real time — automating key tasks like inventory management and disruption mitigation. In addition, its agentic AI framework will enable companies to easily create their own AI agents on Maestro, making AI-driven supply chain orchestration accessible to businesses
Verne Strikes 10MW Deal with Nebius to Further Expand Europe’s AI Capacity11.3.2025 12:00:00 EET | Press release
Verne, the leading provider of sustainably powered HPC data centers across the Nordics, has today announced that Nebius, a leading global AI infrastructure provider, will be colocating a cluster of NVIDIA H200 GPUs at Verne’s data center campus in Iceland. This collaboration marks the largest single implementation in Verne Iceland’s history, with Nebius deploying a 10MW cluster. This installation is part of Nebius’ ambitious build-out of AI infrastructure across the US and Europe, supporting its mission to provide scalable, energy-efficient solutions for intensive AI workloads. As one of Europe’s leading providers of GPU capacity, Nebius selected Verne for its proven expertise, renewable energy-driven operations, and ability to meet precise technical and geographical requirements. Verne’s Icelandic facility, uniquely located on a former NATO base and powered entirely by Iceland’s 100% renewable hydroelectric and geothermal energy resources, aligns perfectly with Nebius’ approach to ado
Allegro DVT Launches its First AI-Based Neural Video Processing IP11.3.2025 11:35:00 EET | Press release
Allegro DVT, a leader in video processing semiconductor solutions, is excited to announce the launch of its latest innovation, its first AI-based Neural Video Processing NVP300 IP. This groundbreaking product marks Allegro DVT’s commitment to embrace the AI revolution and push video quality to the next level, leveraging the advanced features and benefits of AI based video processing technologies. The new NVP300 semiconductor IP features an optimized hardware implementation to deliver real-time AI processing of 4K video within best-in-class silicon area and power budget suitable for embedded products. "We are thrilled to introduce our first AI-based Neural Video Processing IP to the market," said Nouar Hamze, CEO at Allegro DVT. "The NVP300 represents a significant advancement in video processing technology offering stunning subjective video quality improvements. It will greatly benefit our customers to power their next generation video compression solutions." The launch of the AI-based
Interactive Brokers Expands Global Reach with Ljubljana Stock Exchange Access11.3.2025 11:00:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced today that it has expanded its market offerings by adding access to the Ljubljana Stock Exchange. With this expansion, clients can trade Slovenian equities alongside products from over 160 other global exchanges, including stocks, options, futures, currencies, bonds, funds, and more, from a single unified platform. Enhancing Market Access for Global Investors Interactive Brokers provides access to over 160 markets across the Americas, Europe, and Asia, and adding the Ljubljana Stock Exchange further broadens the investment opportunities for our active traders and institutional investors. Clients can now include Slovenian stocks as part of their portfolio diversification strategies, complementing their European and global investments. "Interactive Brokers continues to expand its market coverage to meet the needs of global investors," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Add
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom